Compare SN & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SN | JAZZ |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 10.8B |
| IPO Year | N/A | 2007 |
| Metric | SN | JAZZ |
|---|---|---|
| Price | $101.20 | $173.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | $126.29 | ★ $194.40 |
| AVG Volume (30 Days) | ★ 2.3M | 1.5M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.74 | N/A |
| EPS | ★ 4.05 | N/A |
| Revenue | ★ $6,084,941,000.00 | $4,157,832,999.00 |
| Revenue This Year | $18.26 | $5.80 |
| Revenue Next Year | $11.75 | $6.06 |
| P/E Ratio | $25.03 | ★ N/A |
| Revenue Growth | ★ 18.87 | 4.14 |
| 52 Week Low | $60.50 | $95.49 |
| 52 Week High | $128.51 | $182.99 |
| Indicator | SN | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 64.21 | 66.05 |
| Support Level | $83.21 | $172.19 |
| Resistance Level | $90.53 | $182.75 |
| Average True Range (ATR) | 4.20 | 6.09 |
| MACD | 1.75 | 1.42 |
| Stochastic Oscillator | 96.49 | 77.50 |
SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.